NAD biosynthesis in humans - enzymes, metabolites and therapeutic aspects

Current Topics in Medicinal Chemistry

Volumn 13, Issue 23, 2013, Pages 2907-2917

  Dölle, Christian ^a   Skoge, Renate Hvidsten ^a   VanLinden, Magali R ^a   Ziegler, Mathias ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cancer; Compartmentation; Metabolism; Niacin; Signaling; Sirtuins; Vitamin B3

Indexed keywords

DAPORINAD; GMX 1777; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE SYNTHASE; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE RIBOSIDE; NICOTINIC ACID; OLAPARIB; PHOSPHORIBOSYL PYROPHOSPHATE; PHOSPHORIBOSYLTRANSFERASE; PYRIDINE NUCLEOTIDE; QUINOLINIC ACID; SIRTUIN; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ALZHEIMER DISEASE; AMIDATION; ARTICLE; AUTOPHOSPHORYLATION; CELL DEATH; DEACETYLATION; DIET SUPPLEMENTATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GEL FILTRATION; GENE LOCUS; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE METABOLISM; PROTEIN ASSEMBLY; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

BIOMEDICAL RESEARCH; ENZYMES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAD; NEOPLASMS;

EID: 84889046051     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660206     Document Type: Article

References (102)

1. Elvehjem, C. A. M., R. J.; Strong, F. M.; Wooley, D. W. The Isolation and Identification of the anti-black tongue disease factor. J. Biol. Chem., 1938, 123, 137-149.
2. Agledal, L.; Niere, M.; Ziegler, M. The phosphate makes a difference: cellular functions of NADP. Redox Rep., 2010, 15, 2-10.
3. Lee, H. C. Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization. J. Biol. Chem., 2012, 287, 31633-31640.
4. Berger, F.; Ramirez-Hernandez, M. H.; Ziegler, M. The new life of a centenarian: signalling functions of NAD(P). Trends Biochem. Science, 2004, 29, 111-118.
5. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADPribose): novel functions for an old molecule. Nat Rev. Mol. Cell Biol., 2006, 7, 517-528.
6. Sebastian, C.; Satterstrom, F. K.; Haigis, M. C.; Mostoslavsky, R. From sirtuin biology to human diseases: an update. J. Biol. Chem., 2012, 287, 42444-42452.
7. Houtkooper, R. H.; Auwerx, J. Exploring the therapeutic space around NAD+. J. Cell Biol., 2012, 199, 205-209.
8. Imai, S. A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol. Res., 2010, 62, 42-47.
9. Rongvaux, A.; Andris, F.; Van Gool, F.; Leo, O. Reconstructing eukaryotic NAD metabolism. Bioessays., 2003, 25, 683-690.
10. Gossmann, T. I.; Ziegler, M.; Puntervoll, P.; de Figueiredo, L. F.; Schuster, S.; Heiland, I. NAD(+) biosynthesis and salvage-a phylogenetic perspective. FEBS J., 2012, 279, 3355-3363.
11. Andreoli, A. J.; Ikeda, M.; Nishizuka, Y.; Hayaishi, O. Quinolinic acid: a precursor to nicotinamide adenine dinucleotide in Escherichia coli. Biochem. Biophys. Res. Commun., 1963, 12, 92-97.
12. Fukuoka, S.; Nyaruhucha, C. M.; Shibata, K. Characterization and functional expression of the cDNA encoding human brain quinolinate phosphoribosyltransferase. Biochim. 0 Et Biophys. Acta-Gene Struct. Expression., 1998, 1395, 192-201.
13. Liu, H.; Woznica, K.; Catton, G.; Crawford, A.; Botting, N.; Naismith, J. H. Structural and kinetic characterization of quinolinate phosphoribosyltransferase (hQPRTase) from homo sapiens. J. Mol. Biol., 2007, 373, 755-763.
14. Okuno, E.; White, R. J.; Schwarcz, R. Quinolinic acid phosphoribosyltransferase: purification and partial characterization from human liver and brain. J. Biochem., 1988, 103, 1054-1059.
15. Eads, J. C.; Ozturk, D.; Wexler, T. B.; Grubmeyer, C.; Sacchettini, J. C. A new function for a common fold: the crystal structure of quinolinic acid phosphoribosyltransferase. Structure, 1997, 5, 47-58.
16. Terakata, M.; Fukuwatari, T.; Sano, M.; Nakao, N.; Sasaki, R.; Fukuoka, S. I.; Shibata, K. Establishment of True Niacin Deficiency in Quinolinic Acid Phosphoribosyltransferase Knockout Mice. J. Nutr., 2012, 142, 2148-2153.
17. Guillemin, G. J. Quinolinic acid, the inescapable neurotoxin. FEBS J., 2012, 279, 1356-1365.
18. Samal, B.; Sun, Y.; Stearns, G.; Xie, C.; Suggs, S.; McNiece, I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell Biol., 1994, 14, 1431-1437.
19. Fukuhara, A.; Matsuda, M.; Nishizawa, M.; Segawa, K.; Tanaka, M.; Kishimoto, K.; Matsuki, Y.; Murakami, M.; Ichisaka, T.; Murakami, H.; Watanabe, E.; Takagi, T.; Akiyoshi, M.; Ohtsubo, T.; Kihara, S.; Yamashita, S.; Makishima, M.; Funahashi, T.; Yamanaka, S.; Hiramatsu, R.; Matsuzawa, Y.; Shimomura, I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005, 307, 426-430.
20. Imai, S. "Clocks" in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim. Biophys. Acta., 2010, 1804, 1584-1590.
21. Hara, N.; Yamada, K.; Shibata, T.; Osago, H.; Tsuchiya, M. Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS One, 2011, 6, e22781-11.
22. Dahl, T. B.; Holm, S.; Aukrust, P.; Halvorsen, B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu. Rev. Nutr., 2012, 32, 229-243.
23. Burgos, E. S.; Schramm, V. L. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochem., 2008, 47, 11086-11096.
24. Hara, N.; Yamada, K.; Shibata, T.; Osago, H.; Hashimoto, T.; Tsuchiya, M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J. Biol. Chem., 2007, 282, 24574-24582.
25. Burgos, E. S.; Ho, M. C.; Almo, S. C.; Schramm, V. L. A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT. Proc. Natl. Acad. Sci. U S A., 2009, 106, 13748-13753.
26. Takahashi, R.; Nakamura, S.; Nakazawa, T.; Minoura, K.; Yoshida, T.; Nishi, Y.; Kobayashi, Y.; Ohkubo, T. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J. Biochem., 2010, 147, 95-107.
27. Khan, J. A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol., 2006, 13, 582-588.
28. Kim, M. K.; Lee, J. H.; Kim, H.; Park, S. J.; Kim, S. H.; Kang, G. B.; Lee, Y. S.; Kim, J. B.; Kim, K. K.; Suh, S. W.; Eom, S. H. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J. Mol. Biol., 2006, 362, 66-77.
29. Wang, T.; Zhang, X.; Bheda, P.; Revollo, J. R.; Imai, S.; Wolberger, C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol., 2006, 13, 661-662.
30. Zhang, L. Q.; Heruth, D. P.; Ye, S. Q. Nicotinamide Phosphoribosyltransferase in Human Diseases. J. Bioanal. Biomed., 2011, 3, 13-25.
31. Pedersen, P. L. The cancer cell's "power plants" as promising therapeutic targets: an overview. J. Bioenerg. Biomembr., 2007, 39, 1-12.
32. Hasmann, M.; Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res., 2003, 63, 7436-7442.
33. Bi, T. Q.; Che, X. M. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther., 2010, 10, 119-125.
34. Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov., 2011, 10, 671-684.
35. Menssen, A.; Hydbring, P.; Kapelle, K.; Vervoorts, J.; Diebold, J.; Luscher, B.; Larsson, L. G.; Hermeking, H. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc. Natl. Acad Sci. U S A., 2012, 109, E187-196.
36. Nikiforov, A.; Dölle, C.; Niere, M.; Ziegler, M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J. Biol. Chem., 2011, 286, 21767-21778.
37. Chiarugi, A.; Dölle, C.; Felici, R.; Ziegler, M. The NAD metabolome-a key determinant of cancer cell biology. Nat. Rev. Cancer., 2012, 12, 741-752.
38. Bajrami, I.; Kigozi, A.; Van Weverwijk, A.; Brough, R.; Frankum, J.; Lord, C. J.; Ashworth, A. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol. Med., 2012, 4, 1087-1096.
39. Galassi, L.; Di Stefano, M.; Brunetti, L.; Orsomando, G.; Amici, A.; Ruggieri, S.; Magni, G. Characterization of human nicotinate phosphoribosyltransferase: Kinetic studies, structure prediction and functional analysis by site-directed mutagenesis. Biochimie., 2012, 94, 300-309.
40. Gross, J.; Rajavel, M.; Segura, E.; Grubmeyer, C. Energy coupling in Salmonella typhimurium nicotinic acid phosphoribosyltransferase: identification of His-219 as site of phosphorylation. Biochemistry., 1996, 35, 3917-3924.
41. Rajavel, M.; Lalo, D.; Gross, J. W.; Grubmeyer, C. Conversion of a cosubstrate to an inhibitor: phosphorylation mutants of nicotinic acid phosphoribosyltransferase. Biochemistry., 1998, 37, 4181-4188.
42. Imsande, J.; Handler, P. Biosynthesis of diphosphopyridine nucleotide. III. Nicotinic acid mononucleotide pyrophos-phorylase. J. Biol. Chem., 1961, 236, 525-530.
43. Niedel, J.; Dietrich, L. S. Nicotinate phosphoribosyltransferase of human erythrocytes. Purification and properties. J. Biol. Chem., 1973, 248, 3500-3505.
44. Smith, L. D.; Gholson, R. K. Allosteric properties of bovine liver nicotinate phosphoribosyltransferase. J. Biol. Chem., 1969, 244, 68-71.
45. Chappie, J. S.; Canaves, J. M.; Han, G. W.; Rife, C. L.; Xu, Q.; Stevens, R. C. The structure of a eukaryotic nicotinic acid phosphoribosyltransferase reveals structural heterogeneity among type II PRTases. Structure., 2005, 13, 1385-1396.
46. Shin, D. H.; Oganesyan, N.; Jancarik, J.; Yokota, H.; Kim, R.; Kim, S. H. Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum. J. Biol. Chem., 2005, 280, 18326-18335.
47. Watson, M.; Roulston, A.; Belec, L.; Billot, X.; Marcellus, R.; Bedard, D.; Bernier, C.; Branchaud, S.; Chan, H.; Dairi, K.; Gilbert, K.; Goulet, D.; Gratton, M. O.; Isakau, H.; Jang, A.; Khadir, A.; Koch, E.; Lavoie, M.; Lawless, M.; Nguyen, M.; Paquette, D.; Turcotte, E.; Berger, A.; Mitchell, M.; Shore, G. C.; Beauparlant, P. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell Biol., 2009, 29, 5872-5888.
48. Olesen, U. H.; Thougaard, A. V.; Jensen, P. B.; Sehested, M. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol. Cancer Ther., 2010, 9, 1609-1617.
49. Kei, A.; Elisaf, M. S. Nicotinic acid: clinical considerations. Expert Opin. Drug Saf., 2012, 11, 551-564.
50. Bieganowski, P.; Brenner, C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell., 2004, 117, 495-502.
51. Dölle, C.; Ziegler, M. Application of a coupled enzyme assay to characterize nicotinamide riboside kinases. Anal. Biochem., 2009, 385, 377-379.
52. Khan, J. A.; Xiang, S.; Tong, L. Crystal structure of human nicotinamide riboside kinase. Structure., 2007, 15, 1005-1013.
53. Tempel, W.; Rabeh, W. M.; Bogan, K. L.; Belenky, P.; Wojcik, M.; Seidle, H. F.; Nedyalkova, L.; Yang, T.; Sauve, A. A.; Park, H. W.; Brenner, C. Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol., 2007, 5, e263.
54. Sasiak, K.; Saunders, P. P. Purification and properties of a human nicotinamide ribonucleoside kinase. Arch. Biochem. Biophys., 1996, 333, 414-418.
55. Goody, M. F.; Kelly, M. W.; Lessard, K. N.; Khalil, A.; Henry, C. A. Nrk2b-mediated NAD+ production regulates cell adhesion and is required for muscle morphogenesis in vivo: Nrk2b and NAD+ in muscle morphogenesis. Dev. Biol., 2010, 344, 809-826.
56. Raffaelli, N.; Sorci, L.; Amici, A.; Emanuelli, M.; Mazzola, F.; Magni, G. Identification of a novel human nicotinamide mononucleotide adenylyltransferase. Biochem Biophys Res Commun., 2002, 297, 835-840.
57. Zhang, X.; Kurnasov, O. V.; Karthikeyan, S.; Grishin, N. V.; Osterman, A. L.; Zhang, H. Structural characterization of a human cytosolic NMN/NaMN adenylyltransferase and implication in human NAD biosynthesis. J. Biol. Chem., 2003, 278, 13503-13511.
58. Emanuelli, M.; Carnevali, F.; Saccucci, F.; Pierella, F.; Amici, A.; Raffaelli, N.; Magni, G. Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial expression, and enzymatic properties of human NMN adenylyltransferase. J. Biol. Chem., 2001, 276, 406-412.
59. Schweiger, M.; Hennig, K.; Lerner, F.; Niere, M.; Hirsch-Kauffmann, M.; Specht, T.; Weise, C.; Oei, S. L.; Ziegler, M. Characterization of recombinant human nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD synthesis. FEBS Lett., 2001, 492, 95-100.
60. Berger, F.; Lau, C.; Ziegler, M. Regulation of poly(ADP-ribose) polymerase 1 activity by the phosphorylation state of the nuclear NAD biosynthetic enzyme NMN adenylyl transferase 1. Proc. Natl. Acad Sci. U S A., 2007, 104, 3765-3770.
61. Berger, F.; Lau, C.; Dahlmann, M.; Ziegler, M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem., 2005, 280, 36334-36341.
62. Zhang, T.; Berrocal, J. G.; Yao, J.; DuMond, M. E.; Krishnakumar, R.; Ruhl, D. D.; Ryu, K. W.; Gamble, M. J.; Kraus, W. L. Regulation of poly(ADP-ribose) polymerase-1-dependent gene expression through promoter-directed recruitment of a nuclear NAD+ synthase. J. Biol. Chem., 2012, 287, 12405-12416.
63. Zhang, T.; Berrocal, J. G.; Frizzell, K. M.; Gamble, M. J.; DuMond, M. E.; Krishnakumar, R.; Yang, T.; Sauve, A. A.; Kraus, W. L. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J. Biol. Chem., 2009, 284, 20408-20417.
64. Gilley, J.; Coleman, M. P. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol., 2010, 8, e1000300.
65. Lau, C.; Niere, M.; Ziegler, M. The NMN/NaMN adenylyltransferase (NMNAT) protein family. Front Biosci., 2009, 14, 410-431.
66. Araki, T.; Sasaki, Y.; Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science, 2004, 305, 1010-1013.
67. Lau, C.; Dölle, C.; Gossmann, T. I.; Agledal, L.; Niere, M.; Ziegler, M. Isoform-specific targeting and interaction domains in human nicotinamide mononucleotide adenylyltransferases. J. Biol. Chem., 2010, 285, 18868-18876.
68. Sorci, L.; Cimadamore, F.; Scotti, S.; Petrelli, R.; Cappellacci, L.; Franchetti, P.; Orsomando, G.; Magni, G. Initial-rate kinetics of human NMN-adenylyltransferases: substrate and metal ion specificity, inhibition by products and multisubstrate analogues, and isozyme contributions to NAD+ biosynthesis. Biochem., 2007, 46, 4912-4922.
69. Magni, G.; Amici, A.; Emanuelli, M.; Orsomando, G.; Raffaelli, N.; Ruggieri, S. Enzymology of NAD+ homeostasis in man. Cell. Mol. Life Sci., 2004, 61, 19-34.
70. Zhai, R. G.; Rizzi, M.; Garavaglia, S. Nicotinamide/nicotinic acid mononucleotide adenylyltransferase, new insights into an ancient enzyme. Cell. Mol. Life Sci., 2009, 66, 2805-2818.
71. Brunetti, L.; Di Stefano, M.; Ruggieri, S.; Cimadamore, F.; Magni, G. Homology modeling and deletion mutants of human nicotinamide mononucleotide adenylyltransferase isozyme 2: new insights on structure and function relationship. Protein Sci., 2010, 19, 2440-2450.
72. Garavaglia, S.; D'Angelo, I.; Emanuelli, M.; Carnevali, F.; Pierella, F.; Magni, G.; Rizzi, M. Structure of human NMN adenylyltransferase. A key nuclear enzyme for NAD homeostasis. J. Biol. Chem., 2002, 277, 8524-8530.
73. Werner, E.; Ziegler, M.; Lerner, F.; Schweiger, M.; Heinemann, U. Crystal structure of human nicotinamide mononucleotide adenylyltransferase in complex with NMN. FEBS. Lett., 2002, 516, 239-244.
74. Zhou, T.; Kurnasov, O.; Tomchick, D. R.; Binns, D. D.; Grishin, N. V.; Marquez, V. E.; Osterman, A. L.; Zhang, H. Structure of human nicotinamide/nicotinic acid mononucleotide adenylyltransferase. Basis for the dual substrate specificity and activation of the oncolytic agent tiazofurin. J. Biol. Chem., 2002, 277, 13148-13154.
75. Mayer, P. R.; Huang, N.; Dewey, C. M.; Dries, D. R.; Zhang, H.; Yu, G. Expression, localization, and biochemical characterization of nicotinamide mononucleotide adenylyltransferase 2. J. Biol. Chem., 2010, 285, 40387-40396.
76. Conforti, L.; Janeckova, L.; Wagner, D.; Mazzola, F.; Cialabrini, L.; Di Stefano, M.; Orsomando, G.; Magni, G.; Bendotti, C.; Smyth, N.; Coleman, M. Reducing expression of NAD+ synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration. FEBS J., 2011, 278, 2666-2679.
77. Branster, M. V.; Morton, R. K. Comparative rates of synthesis of diphosphopyridine nucleotide by normal and tumour tissue from mouse mammary gland; studies with isolated nuclei. Biochem. J., 1956, 63, 640-646.
78. Ohira, M.; Kageyama, H.; Mihara, M.; Furuta, S.; Machida, T.; Shishikura, T.; Takayasu, H.; Islam, A.; Nakamura, Y.; Takahashi, M.; Tomioka, N.; Sakiyama, S.; Kaneko, Y.; Toyoda, A.; Hattori, M.; Sakaki, Y.; Ohki, M.; Horii, A.; Soeda, E.; Inazawa, J.; Seki, N.; Kuma, H.; Nozawa, I.; Nakagawara, A. Identification and characterization of a 500-kb homozygously deleted region at 1p36. 2-p36. 3 in a neuroblastoma cell line. Oncogene., 2000, 19, 4302-4307.
79. Ma, J.; Gao, M.; Lu, Y.; Feng, X.; Zhang, J.; Lin, D.; Xiao, T.; Hu, Z.; Yuan, J.; Su, K.; Shipley, J.; Xue, J.; Gao, Y. Gain of 1q25-32, 12q23-24. 3, and 17q12-22 facilitates tumorigenesis and progression of human squamous cell lung cancer. J. Pathol., 2006, 210, 205-213.
80. Waller, A. Experiments on the Section of the Glossopharyngeal and Hypoglossal Nerves of the Frog, and Observations of the Alterations Produced Thereby in the Structure of Their Primitive Fibres. Philos. Trans. R. Soc. Lond B. Biol. Sci., 1850, 140, 423-429.
81. Coleman, M. P.; Freeman, M. R. Wallerian degeneration, wld(s), and nmnat. Annu. Rev. Neurosci., 2010, 33, 245-267.
82. Lunn, E. R.; Perry, V. H.; Brown, M. C.; Rosen, H.; Gordon, S. Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur. J. Neurosci., 1989, 1, 27-33.
83. Mack, T. G.; Reiner, M.; Beirowski, B.; Mi, W.; Emanuelli, M.; Wagner, D.; Thomson, D.; Gillingwater, T.; Court, F.; Conforti, L.; Fernando, F. S.; Tarlton, A.; Andressen, C.; Addicks, K.; Magni, G.; Ribchester, R. R.; Perry, V. H.; Coleman, M. P. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat. Neurosci., 2001, 4, 1199-1206.
84. Coleman, M. P.; Conforti, L.; Buckmaster, E. A.; Tarlton, A.; Ewing, R. M.; Brown, M. C.; Lyon, M. F.; Perry, V. H. An 85-kb tandem triplication in the slow Wallerian degeneration (Wlds) mouse. Proc. Natl. Acad. Sci. U S A., 1998, 95, 9985-9990.
85. Yan, T.; Feng, Y.; Zheng, J.; Ge, X.; Zhang, Y.; Wu, D.; Zhao, J.; Zhai, Q. Nmnat2 delays axon degeneration in superior cervical ganglia dependent on its NAD synthesis activity. Neurochem. Int., 2010, 56, 101-106.
86. Chiang, P. W.; Wang, J.; Chen, Y.; Fu, Q.; Zhong, J.; Chen, Y.; Yi, X.; Wu, R.; Gan, H.; Shi, Y.; Chen, Y.; Barnett, C.; Wheaton, D.; Day, M.; Sutherland, J.; Heon, E.; Weleber, R. G.; Gabriel, L. A.; Cong, P.; Chuang, K.; Ye, S.; Sallum, J. M.; Qi, M. Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat. Genet., 2012, 44, 972-974.
87. Falk, M. J.; Zhang, Q.; Nakamaru-Ogiso, E.; Kannabiran, C.; Fonseca-Kelly, Z.; Chakarova, C.; Audo, I.; Mackay, D. S.; Zeitz, C.; Borman, A. D.; Staniszewska, M.; Shukla, R.; Palavalli, L.; Mohand-Said, S.; Waseem, N. H.; Jalali, S.; Perin, J. C.; Place, E.; Ostrovsky, J.; Xiao, R.; Bhattacharya, S. S.; Consugar, M.; Webster, A. R.; Sahel, J. A.; Moore, A. T.; Berson, E. L.; Liu, Q.; Gai, X.; Pierce, E. A. NMNAT1 mutations cause Leber congenital amaurosis. Nat. Genet., 2012, 44, 1040-1045.
88. Koenekoop, R. K.; Wang, H.; Majewski, J.; Wang, X.; Lopez, I.; Ren, H.; Chen, Y.; Li, Y.; Fishman, G. A.; Genead, M.; Schwartzentruber, J.; Solanki, N.; Traboulsi, E. I.; Cheng, J.; Logan, C. V.; McKibbin, M.; Hayward, B. E.; Parry, D. A.; Johnson, C. A.; Nageeb, M.; Finding of Rare Disease Genes Canada, C.; Poulter, J. A.; Mohamed, M. D.; Jafri, H.; Rashid, Y.; Taylor, G. R.; Keser, V.; Mardon, G.; Xu, H.; Inglehearn, C. F.; Fu, Q.; Toomes, C.; Chen, R. Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat. Genet., 2012, 44, 1035-1039.
89. Perrault, I.; Hanein, S.; Zanlonghi, X.; Serre, V.; Nicouleau, M.; Defoort-Delhemmes, S.; Delphin, N.; Fares-Taie, L.; Gerber, S.; Xerri, O.; Edelson, C.; Goldenberg, A.; Duncombe, A.; Le Meur, G.; Hamel, C.; Silva, E.; Nitschke, P.; Calvas, P.; Munnich, A.; Roche, O.; Dollfus, H.; Kaplan, J.; Rozet, J. M. Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat. Genet., 2012, 44, 975-977.
90. Pierce, E. A. Pathways to photoreceptor cell death in inherited retinal degenerations. Bioessays., 2001, 23, 605-618.
91. Pace, H. C.; Brenner, C. The nitrilase superfamily: classification, structure and function. Genome Biol., 2001, 2, REVIEWS0001.
92. Bieganowski, P.; Pace, H. C.; Brenner, C. Eukaryotic NAD+ synthetase Qns1 contains an essential, obligate intramolecular thiol glutamine amidotransferase domain related to nitrilase. J. Biol. Chem., 2003, 278, 33049-33055.
93. Hara, N.; Yamada, K.; Terashima, M.; Osago, H.; Shimoyama, M.; Tsuchiya, M. Molecular identification of human glutamine-and ammonia-dependent NAD synthetases. Carbon-nitrogen hydrolase domain confers glutamine dependency. J. Biol. Chem., 2003, 278, 10914-10921.
94. LaRonde-LeBlanc, N.; Resto, M.; Gerratana, B. Regulation of active site coupling in glutamine-dependent NAD(+) synthetase. Nat. Struct. Mol. Biol., 2009, 16, 421-429.
95. Bieganowski, P.; Brenner, C. The reported human NADsyn2 is ammonia-dependent NAD synthetase from a pseudomonad. J. Biol. Chem., 2003, 278, 33056-33059.
96. Sorci, L.; Pan, Y.; Eyobo, Y.; Rodionova, I.; Huang, N.; Kurnasov, O.; Zhong, S.; MacKerell, A. D., Jr.; Zhang, H.; Osterman, A. L. Targeting NAD biosynthesis in bacterial pathogens: Structurebased development of inhibitors of nicotinate mononucleotide adenylyltransferase NadD Chem. Biol., 2009, 16, 849-861.
97. Moro, W. B.; Yang, Z.; Kane, T. A.; Brouillette, C. G.; Brouillette, W. J. Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs). Bioorg. Med. Chem. Lett., 2009, 19, 2001-2005.
98. Gong, B.; Pan, Y.; Vempati, P.; Zhao, W.; Knable, L.; Ho, L.; Wang, J.; Sastre, M.; Ono, K.; Sauve, A. A.; Pasinetti, G. M. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging., 2013, 34, 1581-1588.
99. Canto, C.; Houtkooper, R. H.; Pirinen, E.; Youn, D. Y.; Oosterveer, M. H.; Cen, Y.; Fernandez-Marcos, P. J.; Yamamoto, H.; Andreux, P. A.; Cettour-Rose, P.; Gademann, K.; Rinsch, C.; Schoonjans, K.; Sauve, A. A.; Auwerx, J. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab., 2012, 15, 838-847.
100. Yoshino, J.; Mills, K. F.; Yoon, M. J.; Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet-and age-induced diabetes in mice. Cell Metab., 2011, 14, 528-536.
101. Shi, F.; Li, Y.; Li, Y.; Wang, X. Molecular properties, functions, and potential applications of NAD kinases. Acta Biochim. Biophys. Sin (Shanghai)., 2009, 41, 352-361.
102. Wang, B.; Hasan, M. K.; Alvarado, E.; Yuan, H.; Wu, H.; Chen, W. Y. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene., 2011, 30, 907-921.